A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The researchers assessed whether a 3-month therapeutic assessment with GH therapy could be used to determine which GHD adults should be treated over the longer term.

The researchers also assessed the continued prescription of GH by general practitioners (GPs) following the initial therapeutic assessment.

Who Took Part

According to the abstract, 24 subjects were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

A three month open therapeutic trial of GH in GHD adults.

All adult GHD patients were considered for GH therapy.

How the Study Was Run

After completion of the three months the continued prescription of GH by the GPs was assessed.

Thirty-nine GHD adults wanted GH therapy (group 1) and their baseline characteristics such as age, duration of GHD, and IGF-1 concentration were compared with 24 subjects who declined to receive GH (group 2).

Measurements of body composition using bioelectrical impedance analysis, lipids and quality of life measured using a dedicated questionnaire were made before and after GH therapy.

The response of the general practitioners to continued GH therapy after the initial therapeutic assessment was also noted.

What Was Measured

PubMed files the paper under topics including Growth Hormone, Human Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor I, Refusal to Treat and Treatment Refusal.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.